临床外科杂志 ›› 2021, Vol. 29 ›› Issue (5): 422-427.doi: 10.3969/j.issn.1005-6483.2021.05.008

• • 上一篇    下一篇

新辅助放化疗治疗局部进展期直肠癌的远期疗效及预后因素分析

  

  1. 100020 首都医科大学附属北京朝阳医院普外科
  • 出版日期:2021-05-20 发布日期:2021-05-20
  • 通讯作者: 韩加刚,Email:hjg211@163.com;王振军,Email:wang3sj@Soho. com

Post-operative ypN stage is independent risk factor for locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy

  1. Department of General Surgery,Beijing Chaoyang Hosptial,Capital Medical University,Beijing 100020,China
  • Online:2021-05-20 Published:2021-05-20

摘要: 目的  分析新辅助放化疗(nCRT)治疗局部进展期直肠癌的远期疗效及预后影响因素。
方法  回顾性分析我院普外科2013年1月~2016年1月收治的局部进展期直肠癌病人的临床资料。随访病人5年总体存活率(OS)和无病存活率(DFS),采用单因素分析和Cox回归模型分析影响生存预后的危险因素。
结果  共纳入完成nCRT并接受根治性手术的局部进展期直肠癌病人97例。中位随访时间39个月(6~83个月),远处转移16例(16.5%),肿瘤复发8例(8.3%)。病人5年OS和DFS分别为77.4%和75.1%,远处转移病人的5年OS显著降低(37.5% vs.76.8%,P=0.022)。单因素分析结果发现,ypTNM分期晚(χ2=11.282,P=0.01)、ypN+(χ2=8.134,P=0.004)以及非病理完全缓解(χ2=4.550,P=0.033)与nCRT后直肠癌病人OS降低显著相关;ypN+(χ2=5.007,P=0.025)和脉管浸润(χ2=3.330,P=0.048)与DFS降低显著相关。Cox多因素分析发现,ypN+是nCRT后病人OS(HR=3.006,95%CI:1.220~7.407,P=0.017)和DFS(HR=2.998,95%CI:1.138~7.894,P=0.026)的独立危险因素。
结论  ypN+是局部进展期直肠癌生存预后的独立危险因素,术后针对高危病人进行强化治疗可能有助于改善远期预后。

关键词: 新辅助放化疗, 局部进展期直肠癌, 远期疗效, 预后因素

Abstract: Objective To further evaluate the long-term survival benefits and prognostic analysis of locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy.
Methods Clinical characteristics of locally advanced rectal cancer patients were retrospectively collected from January,2013 to January,2016 in the Department of General Surgery of Beijing Chaoyang Hospital.Kaplan-Meier for survival curve and log-rank test for univariate prognostic analysis,Cox proportional hazard model was used for multivariate analysis.
Results A total of 97 rectal cancer patients were included.All patients received nCRT and TME.The median follow-up time was 39(6~83) months.The cumulative 5-OS and DFS were 77.4% and 74.1% respectively.Univariate prognostic analysis revealed that advanced ypTNM stage(χ2=11.282,P=0.01),ypN+(χ2=8.134,P=0.004) and non-pCR(χ2=4.550,P=0.033) patients had a worse OS,while ypN+(χ2=5.007,P=0.025) and lymphvascular invasion(χ2=3.330,P=0.048) were significantly associated with decreased DFS.Multivariate analysis showed that ypN stage was independent risk factor for both OS(HR=3.006,95%CI:1.220~7.407,P=0.017)and DFS(HR=2.998,95%CI:1.138~7.894,P=0.026).
Conclusion ypN+ was independent risk factor for both OS and DSF for locally advanced rectal cancer who received neoadjuvant chemoradiotherapy,and consolidation therapy after nCRT might be benefical for patients with high risk factors.

Key words: neoadjuvant chemoradiotherapy, locally advanced rectal cancer, long-term survival benefits, prognostic analysis

[1] 夏雨佳, 左维维, 王梦园, 胡明. 亚甲基蓝在胃肠道恶性肿瘤淋巴结检获中应用价值的Meta分析[J]. 临床外科杂志, 2020, 28(1): 59-62.
[2] 吴开明, 姚龙, 康宁宁等. 进展期食管癌微创治疗术后远期疗效及预后因素分析[J]. 临床外科杂志, 2019, 27(7): 558-561.
[3] 关树斌, 谷志涛, 茅腾等. 胸腺肿瘤淋巴结转移研究进展[J]. 临床外科杂志, 2019, 27(7): 622-625.
[4] 郑浩, 张仁泉. 局部进展期食管癌新辅助治疗的研究现状[J]. 临床外科杂志, 2019, 27(7): 626-629.
[5] 陶俊 王贵和. 局部进展期直肠癌新辅助放化疗后病理完全缓解的预测因素分析[J]. 临床外科杂志, 2018, 26(10): 756-759.
[6] 周涛 王蓓 吕成余等. 食管胃结合部腺癌221例临床分析[J]. 临床外科杂志, 2013, 21(1): 29-33.
[7] 张安平 刘宝华 李凡 童卫东 付涛 叶景旺. 新辅助放化疗联合手术治疗局部进展期低位直肠癌的疗效分析[J]. 临床外科杂志, 2012, 20(4): 234-234.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 刘俊峰. 食管切除术后患者胸胃功能与生活质量的变化及处理[J]. 临床外科杂志, 2016, 24(7): 546 .
[2] 梁寒. 日本第15版“胃癌处理规约”及第5版“胃癌治疗指南”外科部分更新解读[J]. 临床外科杂志, 2018, 26(1): 22 .
[3] 董汉华, 武齐齐, 陈孝平. 急性胆道感染东京指南(2018版)更新解读[J]. 临床外科杂志, 2019, 27(1): 5 -9 .
[4] 陈香蓉, 权毅. 多灶性多中心性乳腺癌的临床病理特征分析[J]. 临床外科杂志, 2019, 27(1): 55 -58 .
[5] 徐一宏, 徐卫东. 人工髋关节假体材料及界面的选择[J]. 临床外科杂志, 2019, 27(4): 271 -275 .
[6] 鄢建新, 姚勇, 杨安忠. 无菌翻修膝关节置换术23例临床分析[J]. 临床外科杂志, 2019, 27(4): 349 -351 .
[7] 陶凯雄. 腹腔镜胃癌根治术并发症的防治策略[J]. 临床外科杂志, 2019, 27(5): 363 -366 .
[8] 徐诚实, 王庚. 超声定位神经阻滞在膝关节手术中的应用现状及争议[J]. 临床外科杂志, 2019, 27(6): 453 -456 .
[9] 田现钢, 杨岷, 樊纪丹. D-二聚体及C-反应蛋白与DeBakey Ⅲ型主动脉夹层动脉瘤假腔几何参数及预后的相关性分析[J]. 临床外科杂志, 2019, 27(6): 504 -507 .
[10] 康敢军, 黄杰. 颈胸交界处肿瘤的个性化外科治疗[J]. 临床外科杂志, 2019, 27(7): 552 -554 .